Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension

Rajesh Janardhanan, William L. Daley, Tasneem Z. Naqvi, Sharon L. Mulvagh, Gerard Aurigemma, Michael Zile, J. Malcolm O. Arnold, Eunice Artis, Das Purkayastha, James D. Thomas, Scott D. Solomon

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Background: Although 50% of hypertensive patients in the community are estimated to have diastolic dysfunction, there is no specific guideline for diastolic dysfunction therapy at present despite the condition's clear association with increased cardiovascular risk. Although the efficacy of angiotensin II receptor blockers (ARBs) in hypertension and left ventricular hypertrophy regression has been established, the effect of angiotensin II receptor blockade on intrinsic parameters of diastolic function has not been evaluated in large-scale studies. Methods: The VALIDD Trial is an investigator-initiated randomized, controlled, double-blind clinical trial on approximately 350 patients designed to explore whether antihypertensive therapy with the ARB valsartan, in addition to standard therapy, would improve intrinsic diastolic properties of the myocardium in patients with hypertension and evidence of diastolic dysfunction. The result of such therapy will be compared with placebo after 38 weeks of treatment. The primary efficacy variable is change in early diastolic lateral mitral annular relaxation velocity measured by tissue Doppler imaging on week 38. Conclusions: We expect the VALIDD Trial to provide novel insights into the specific effects of ARBs on diastolic dysfunction, as assessed by tissue Doppler imaging, in hypertensive patients. The trial may provide clinically useful data on whether such therapy can directly improve diastolic function in patients with hypertension.

Original languageEnglish (US)
Pages (from-to)246-252
Number of pages7
JournalAmerican Heart Journal
Volume152
Issue number2
DOIs
StatePublished - Aug 1 2006

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension'. Together they form a unique fingerprint.

  • Cite this

    Janardhanan, R., Daley, W. L., Naqvi, T. Z., Mulvagh, S. L., Aurigemma, G., Zile, M., Arnold, J. M. O., Artis, E., Purkayastha, D., Thomas, J. D., & Solomon, S. D. (2006). Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension. American Heart Journal, 152(2), 246-252. https://doi.org/10.1016/j.ahj.2006.01.009